Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment.
10.4306/jknpa.2013.52.4.253
- Author:
Seon Cheol PARK
1
;
Seung Hwan SUNG
;
Kyu Man HAN
;
Eun Soo WON
;
Hwa Young LEE
;
Jong Woo PAIK
;
Hong Jin JEON
;
Moon Soo LEE
;
Se Hoon SHIM
;
Young Hoon KO
;
Kang Joon LEE
;
Changsu HAN
;
Byung Joo HAM
;
Joonho CHOI
;
Heeyoung LEE
;
Tae Yeon HWANG
;
Kang Seob OH
;
Yong Chon PARK
;
Min Soo LEE
;
Sang Woo HAHN
Author Information
1. Department of Psychiatry, Yong-In Mental Hospital, Yongin, Korea.
- Publication Type:Original Article
- Keywords:
Depression;
Pharmacological treatment;
Antidepressant;
Initial choice;
Korean
- MeSH:
Antidepressive Agents;
Antipsychotic Agents;
Bupropion;
Depression;
Humans;
Seasons;
Serotonin Uptake Inhibitors
- From:Journal of Korean Neuropsychiatric Association
2013;52(4):253-262
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of this study is to establish Korean pharmacological treatment guidelines for the initial choice of antidepressant for treatment of moderate or severe depression. METHODS: The process for establishment of guidelines involved determination of important key questions, selection of 12 international and domestic clinical practice guidelines for depression, drawing of recommendation drafts, and peer review. RESULTS: Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRI), and noradrenergic and specific serotonergic antidepressants (NaSSA) were strongly recommended as the first-line antidepressants for treatment of moderate or severe depression. SSRIs were weakly recommended for patients who had problems with tolerability. Consideration of not only efficacy but also provisional adverse effects, drug-drug interactions, history of treatment response, preference, acceptability, cost, comorbid illnesses, and other factors in the choice of first-line antidepressants was strongly recommended. The treatment recommendations for specific clinical features of depression were as follows. SSRIs were weakly recommended for atypical depression. Augmented use of antipsychotics to antidepressants was strongly recommended for psychotic depression. Bupropion and SSRIs were weakly recommended for seasonal depression. CONCLUSION: The results of this study may contribute toward improving the quality of depression treatment by providing clear and definite recommendations for the initial choice of antidepressant for treatment of moderate or severe depression.
